Figure 4. Puerarin inhibits in vitro osteoclastogenesis. (A) CCK-8 assay results show the viability of BMMs treated with 0, 10, 50, 100 and 500 μM puerarin (n=5 per group). (B–C) TRAcP assay analysis shows the numbers of TRAcP-positive cells (>3 nuclei) in BMMs treated with 50 ng/mL M-CSF, 50 ng/mL RANKL, and 0, 10, or 100 μM puerarin. Note: n=3 per group; **P <0.01 vs. the control group. (D, E) TRAcP assay analysis shows the numbers of TRAcP-positive cells in BMMs stimulated with 50 ng/mL M-CSF, 50 ng/mL RANKL and 100 μM puerarin for the indicated days during osteoclastogenesis, Note: n=3 per group, NS: Not statistically significant, **P <0.01 vs. the control group (without puerarin treatment).